Partial volume effect correction in SPECT for striatal uptake measurements in patients with neurodegenerative diseases: Impact upon patient classification

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 33, Issue 9, 2006, Pages 1062-1072

  Soret, Marine ^a,b   Koulibaly, Pierre Malick ^c   Darcourt, Jacques ^c   Buvat, Irène ^a  

^a INSERM   (France)

^b University of Paris Descartes   (France)

^c CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

Brain; Dopamine transporter; Image processing; Lewy body disease; SPECT

Indexed keywords

3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; DOPAMINE TRANSPORTER; IODINE 123; N OMEGA FLUOROPROPYL 2BETA CARBOMETHOXY 3BETA (4 IODOPHENYL)TROPANE I 123; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CORPUS STRIATUM; DEGENERATIVE DISEASE; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DOPAMINERGIC SYSTEM; FEMALE; FOLLOW UP; HUMAN; IMAGE ANALYSIS; IMAGE RECONSTRUCTION; MALE; NEUROLOGIC EXAMINATION; PARTIAL VOLUME EFFECT; PATIENT CODING; PATIENT MONITORING; PUTAMEN; RADIATION ATTENUATION; RADIOLOGICAL PARAMETERS; SIMULATION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

AGED; ALZHEIMER DISEASE; COMPUTER SIMULATION; CORPUS STRIATUM; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LEWY BODY DISEASE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MONTE CARLO METHOD; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 33747052890     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-005-0003-4     Document Type: Article

References (34)

1. 123I] beta-CIT SPECT imaging demonstrate bilateral loss of dopamine transporters in hemi-Parkinson's diseases. Neurology 1996;46:231-237
2. 123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;62:133-140
3. 123I]-FP- CIT study group. Mov Disorder 2000;15:503-510
4. Booij J, Tissingh G, Winogrodzka A, van Royen EA. Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism. Eur J Nucl Med 1999;26:171-182
5. 123I-FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med 2001;28:266-272
6. 2 receptor ligands. Eur J Nucl Med Mol Imaging 2002;29:BP23-BP29
7. Tatsch K. Imaging of the dopaminergic system in parkinsonism with SPET. Nucl Med Commun 2001;22:819-827
8. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113-1124
9. McKeith LG, Ballard CG, Perry RH, Ince PG, O'Brien JT, Neill D et al. Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology 2000;54:1050-1058
10. O'Brien JT, Colloby S, Fenwick J, Williams ED, Firbank M, Burn D et al. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol 2004;61:919-925
11. Walker Z, Costa DC, Walker RW, Shaw K, Gacinovic S, Stevens T et al. Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry 2002;73:134-140
12. Walker Z, Costa DC, Walker RW, Lee L, Livingston G, Jaros E et al. Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: a comparison. Neurology 2004;62:1568-1572
13. Costa DC, Walker Z, Walker RW, Fontes FR. Dementia with Lewy bodies versus Alzheimer's disease: role of dopamine transporter imaging. Mov Disorder 2003;18:S34-S38
14. 2 transporter ligands. Eur J Nucl Med Mol Imaging 2002;29:BP30-BP35
15. Chouker M, Tatsch K, Linke R, Pogarell O, Hahn K, Schwarz J. Striatal dopamine transporter binding in early to moderate advanced Parkinson's disease: monitoring of disease progression over 2 years. Nucl Med Commun 2001;22:721-725
16. Marek K, Seibyl J, Shoulson I. Dopamine transporter brain imaging to assess the effects of Pramipexole vs levodopa on Parkinson disease progression. JAMA 2002;287:1653-1661
17. Hashimoto J, Sasaki T, Ogawa K, Kubo A, Motomura N, Ichihara T et al. Effects of scatter and attenuation correction on quantitative analysis of beta-CIT brain SPET. Nucl Med Commun 1999;20:159-165
18. Almeida P, Ribeiro MJ, Bottlaender M, Loc'h C, Langer O, Strul D et al. Absolute quantitation of iodine-123 epidepride kinetics using single-photon emission tomography: comparison with carbon-11 epidepride and positron emission tomography. Eur J Nucl Med 1999;26:1580-1588
19. 123I SPECT. J Nucl Med 2003;44:1184-1193
20. Hoffman EJ, Huang SC, Phelps ME. Quantitation in positron emission computed tomography: 1. Effect of object size. J Comput Assist Tomogr 1979;3:299-308
21. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 1973;20:415-455
22. 123I-PE2I SPECT. Neuroimage 2003;19:810-816
23. Tissingh G, Booij J, Bergmans P, Winogrodzka A, Janssen AG, van Royen E et al. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iodophenyl) tropane SPECT in healthy controls and early-stage, drug naive Parkinson's disease. J Nucl Med 1998;39:1143-1148
24. Harissson RL, Haynor DR, Gillispie SB, Vannoy SD, Kaplan MS, Lewellen TK. A public-domain simulation system for emission tomography: photon tracking throught heterogeneous attenuation using importance sampling. J Nucl Med 1993;34:60P
25. Ogawa K, Harata Y, Ichihara T, Kubo A, Hashimoto N. A practical method for position-dependent Compton-scattered correction in single photon emission. IEEE Trans Med Imaging 1991;10:408-412
26. Hudson HM, Larkin RS. Accelerated image reconstruction using ordered subsets of projection data. IEEE Trans Med Imaging 1994;13:601-609
27. Tung c-H, Gullberg GT, Zeng GL, Christian PE, Datz FL, Morgan HT. Non-uniform attenuation correction using simultaneous transmission and emission converging tomography. IEEE Trans Nucl Sci 1992;39:1134-1143
28. Maes F, Collignon A, Vandermeulen D, Marchal G, Suetens P. Multimodality image registration by maximization of mutual information. IEEE Trans Med Imaging 1997;16:187-198
29. Rousset OG, Ma Y, Evans AC. Correction for partial volume effects in PET: principle and validation. J Nucl Med 1998;39:904-911
30. Barber R, McKeith I, Ballard C, O'Brien J. Volumetric MRI study of the caudate nucleus in patients with dementia with Lewy bodies, Alzheimer's disease, and vascular dementia. J Neurol Neurosurg Psychiatry 2002;72:406-407
31. Almeida OP, Burton EJ, McKeith I, Gholkar A, Burn D, O'Brien J. MRI study of caudate nucleus volume in Parkinson's disease with and without dementia with Lewy bodies and Alzheimer's disease. Dement Geriatr Cogn Disord 2003;16:57-63
32. Burton EJ, Karas G, Paling SM, Barber R, Williams ED, Ballard C et al. Patterns of cerebral atrophy in dementia with Lewy bodies using voxel-based morphometry. Neuroimage 2002;17:618-630
33. Cousins DA, Burton EJ, Burn D, Gholkar A, McKeith I, O'Brien J. Atrophy of the putamen in dementia with Lewy bodies but not Alzheimer's disease: an MRI study. Neurology 2003;61:1191-1195
34. 123I-beta-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease. Eur J Nucl Med 1997;24:320-325